When mgmt rolls out the update at next Q update looks for strong setups for Strensiq & Kanuma---both $ bil drugs. I wouldn't be surprised to see upward guidance to street estimates for 2016. Lots o positive triggers to keep this Blue Chip biotech performing up 20-40% over the next year++. I am actually quite excited about the net 6/12/24 months & see significant market outperformance.
But don't listen to me ---- I've been involved since $40.....and keep increasing my position----including Recent $150 area. Outstanding
RDUS can a good shot---if the bio tape remains overall strong for developmental plays----to be in the $80s---by yearend '15. More than that would require a M&A story---not likely but certainly possible.
We believe the read-outs for Evofosfamide in pancreatic cancer and sarcoma remain the key THLD catalysts, and the addition of TH-4000fills the early stage pipeline and builds on THLD's expertise in hypoxia.
2016 is shaping up to be a data rich year.
Yes---ALXN can & very likely be a $300+ stock looking out 12-18 months. They have lots more in their bag of tricks that have yet to be publicly disclosed that will likely be very positively received by the investor community. As noted, Strensiq & Kanuma are both $1 bil + opportunities & are already to slide right into a global operation in 50 countries that is prepared to move aggressively on the sales/marketing side. The second half 2015 will provide lots of newsworthy catalysts to push the stock nicely into the $210-220 category.
Very hard for those who KNOW the ALXN story not to be very excited.
Don't concern yourself with Maxim, as they remove their $50 target. $70-75 on RDUS by year-end '15.
Sure looks like it's about to "skyrocket" little beachball ! better tell mommie to stock giving you so much sugar, you're losing it again. maybe you just need a clean dipey.
Ciena has continued to diversify its customer base away from the traditional telcos over the past two years to major players like GOOG FB & AAPL. The story continues to get better as the sustainability of their operating margin grows more evident each quarter. The stock should continue on the upside with a decent shot in the $30-32+ range in 2h15.
"About to skyrocket" ???? oh no !!! we thought you were content to just repost company press releases---you were good at that !! not so good--at all---on your stock forecasts. how many years you been making predictions ??? you funneeeee
more gibberish. the same sloppy slop that this clown puts up when he crawls out from under his rock. you'd think THLD was a $100 stock from the baloney thrown out there...."quants have loaded up big time".
Bakers are smart---only question is why such a small position ?? the stock could quadruple & it would a small amount. They must be waiting for results.
ALXN has an awful t of product announcements n 2H15 which can push the stock to $200 possibly this year & a decent shot at $240--250 looking out a year or so. Strensiq (asfotase alpha) approval in Japan for HPP by mid'15, approval guidance in the US & EU ( but it could come earlier given Breakthrough Designation priority rated 3/02), ALXN1007 (Ph2 data in GI GvHD (mid 2H15 guidance) along with GEVA acq closing shortly. Look for GEVA's Natuna to ramp quickly as ALXN already has feet on the ground already in 50 countries and will penetrate market quicker than GEVA ever could. And that's just the items that have been publicly disclosed. Look for other announcements to provide more upside throughout the upcoming 1-2 quarters.
let's see ... 700 X $3-4....WOW----that's over $2 mil !! how impressive !
There are some index investors as THLD is in an index. There are virtually none of the savvy healthcare investors investing in THLD. As I have noted in the past on numerous occasions they will be happy to buy at $10-15 IF the science bears out & has a decent shot at being commercialized. $50 ????? from your mouth to God's ears ! now THAT would be a great surprise !!!